Biotech / Finance

Circassia signs deal for US rights to two AstraZeneca COPD drugs

From PBR - News
March 20, 2017 - 5:28am
UK-based Circassia Pharmaceuticals has agreed to pay up to $230m for certain US commercial rights for Tudorza and Duaklir, two drugs developed by AstraZeneca to treat chronic obstructive pulmonary disease (COPD).


Continue reading this article »